Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 682 - 682
Published: Feb. 18, 2025
This review is intended to reflect the currently available literature on both clinically significant germline mutations in DNA damage repair (DDR) genes as well importance of ancestral diversity pathogenesis prostate cancer (PCa). The second most prevalent worldwide men PCa, causing morbidity and mortality its advanced stage. Emerging data highlight substantial role DDR PCa pathogenesis, especially progression aggressive forms disease. Germline genetic testing recognized a necessary tool for efficient, individualized patient care. NCCR guidelines recommend inquiring about family history known variants and, if indicated, proceeding with multigene followed by post-test counseling. Depending HR or MMR genes, specific treatment options may provide clinical benefit. We will discuss that are involved prognosis racially diverse populations.
Language: Английский